Compounds that block the generation and / or activity or otherwise, or to bind to more than one complement component 1, the hemolytic disease or other paroxysmal nocturnal hemoglobinuria, to treat, for example, while using a complement inhibitory antibody . In one embodiment, there is provided a...
How I treat autoimmune hemolytic anemias in adults. Autoimmune hemolytic anemia is a heterogeneous disease with respect to the type of the antibody involved and the absence or presence of an underlying condi... K Lechner,U Jager - 《Blood》 被引量: 319发表: 2010年 How I Treat Autoimmune ...
Plasma (fresh frozen plasma), once thawed, is transfused to treat bleeding disorders when many clotting factors are missing. This occurs in liver failure, when too much of a blood thinner called Coumadin has been given, or when severe bleeding and massive transfusions result in low levels of...
Plasma (fresh frozen plasma), once thawed, is transfused to treat bleeding disorders when many clotting factors are missing. This occurs in liver failure, when too much of a blood thinner called Coumadin has been given, or when severe bleeding and massive transfusions result in low levels of...
How I Treat Autoimmune Hemolytic Anemia (Warm Type)doi:10.4103/2468-8398.344346AUTOIMMUNE diseasesHEMOLYTIC anemia treatmentINTRAVENOUS immunoglobulinsLYMPHOPROLIFERATIVE disordersCOOMBS' testDixit, AshishGlobal Journal of Transfusion Medicine
How I treat autoimmune hemolytic anemias in adults. Autoimmune hemolytic anemia is a heterogeneous disease with respect to the type of the antibody involved and the absence or presence of an underlying condi... K Lechner,U Jager - 《Blood》 被引量: 319发表: 2010年 High-dose cyclophosphamide ...
Microangiopathic hemolytic anemia (MAHA) in patients with cancer requires urgent diagnosis and treatment. MAHA associated with thrombocytopenia, suggests a thrombotic microangiopathy (TMA), where there is thrombus formation affecting small or larger vessels. It may be directly related to the underlying...
Introduction to a How I Treat series on acquired hemolytic anemiaMario Cazzola Associate Editor, Blood
One patient carrying two non-missense mutations of the PKLR gene did not respond to treatment with mitapivat. As variations in patient-specific factors (including genotype) can lead to different clinical manifestations and responses to treatment, we recommend considering both the phenotype (clinical ...